WCG acquires biostatistical consultancy Statistics Collaborative

28 January 2020 Consulting.us 2 min. read

WCG, a clinical trial services provider, has announced the acquisition of Statistics Collaborative, a biostatistical consultancy based in Washington, DC. Statistics Collaborative works predominantly with pharmaceutical companies or other organizations developing new drugs or biologics, with a focus on late-stage clinical trials via services such as trial design, data monitoring committee reporting, and data analysis.

"WCG seeks to partner with outstanding companies who share our vision for improving the clinical trial process, while maintaining the highest scientific and ethical standards. We quickly recognized Statistics Collaborative as a company with a similar work ethic, employee culture, and industry goals,” Donald A. Deieso, PhD, executive chairman and CEO of WCG, said. “Statistics Collaborative's exceptional reputation as a leader in biostatistical analysis and consulting for pharmaceutical and biotechnology companies made it a treasured partner to welcome into WCG."

Statistics Collaborative also provides services for epidemiological studies, preclinical studies, and non-clinical research. It has worked in medical areas including cardiovascular diseases, oncology, infectious diseases, orphan diseases, and vaccines.

WCG acquires biostatistical consultancy Statistics Collaborative

Statistics Collaborative will operate under the name WCG Statistics Collaborative, as part of WCG’s scientific and regulatory review division. All of the firm’s staff will join WCG. It will also retain both its leadership structure and Washington, DC headquarters. WCG will provide capital, clinical development expertise, and operational support. Financial details of the acquisition remain undisclosed.

"We are delighted to be joining WCG. Statistics Collaborative had reached an inflection point in our growth. We were looking for a like-minded partner organization, which could provide the requisite resources and infrastructure that would allow our company to continue to evolve while retaining our position as a premier biostatistics partner to the biopharmaceutical industry. We felt that WCG was a good cultural fit for our company,” Janet Wittes, PhD, Statistics Collaborative founder and president, said. “WCG puts the same emphasis on scientific rigor and integrity, and it puts people first – not just patients and clients, but employees, as well. It significantly invests in employee professional development. Statistics Collaborative will continue to provide the same services and deliverables, but with the benefit of additional financial resources and powerful operations and technology platforms that complement our business."